Royal Bank Of Canada Viracta Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$425 Billion
Q2 2024

A detailed history of Royal Bank Of Canada transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 457 shares of VIRX stock, worth $100. This represents 0.0% of its overall portfolio holdings.

Number of Shares

457

Previous 2,068 77.9%

Holding current value

$100

Previous $2,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.5 - $1.17 $805 - $1,884	-1,611 Reduced 77.9%	457 $0
Q1 2024 May 15, 2024	SELL	$0.48 - $1.13 $4,049 - $9,533	-8,437 Reduced 80.31%	2,068 $2,000
Q4 2023 Feb 14, 2024	BUY	$0.44 - $1.04 $3,961 - $9,364	9,004 Added 599.87%	10,505 $5,000
Q3 2023 Nov 14, 2023	BUY	$1.03 - $1.58 $1,241 - $1,903	1,205 Added 407.09%	1,501 $1,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $2.13 $2,412 - $5,774	-2,711 Reduced 90.16%	296 $0
Q1 2023 May 15, 2023	BUY	$1.38 - $2.29 $4,140 - $6,870	3,000 Added 42857.14%	3,007 $4,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $4.38 $8 - $30	7 New	7 $0
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $4,164 - $11,135	-2,227 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $301,897 - $644,408	-135,380 Reduced 98.38%	2,227 $11,000
Q4 2021 Feb 14, 2022	SELL	$3.37 - $7.91 $150,679 - $353,671	-44,712 Reduced 24.52%	137,607 $502,000
Q3 2021 Nov 15, 2021	SELL	$7.84 - $12.53 $95,702 - $152,953	-12,207 Reduced 6.28%	182,319 $1.46 Million
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $1.47 Million - $2.52 Million	194,526 New	194,526 $2.21 Million

Others Institutions Holding VIRX

# of Institutions

Shares Held

9.03M

Call Options Held

10.9K

Put Options Held

400

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $8.26M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Viracta Therapeutics, Inc. Transaction History